Brief: Axovant Presents First Evidence Of Clinical Stabilization In Tay-Sachs Disease At The European Society Of Gene And Cell Therapy 27th Annual Congress

Sio Gene Therapies

23/10/2019 12:25

Oct 23 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT PRESENTS FIRST EVIDENCE OF CLINICAL STABILIZATION
IN
TAY-SACHS DISEASE AT THE EUROPEAN SOCIETY OF GENE AND CELL
THERAPY 27TH ANNUAL CONGRESS
    * AXOVANT GENE THERAPIES LTD - AXO-AAV-GM2 GENERALLY SAFE
AND
WELL-TOLERATED TO DATE
    * AXOVANT GENE THERAPIES LTD - INITIAL DATA WITH AXO-AAV-GM2
SUGGESTS STABILIZATION OF DISEASE COURSE, ATTAINMENT OF NORMAL
DEVELOPMENTAL MILESTONES

Source text for Eikon:  ID:nGNX9SL222 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))